Here are five points:
1. Dr. Mulberg, a pediatric gastroenterologist, will oversee global regulatory strategies for all Amicus programs.
2. Most recently, Dr. Mulberg served as deputy director of the FDA’s Division of Gastroenterology and Inborn Errors Products.
3. He also previously worked in global drug development and medical affairs at pharmaceutical companies, including Johnson & Johnson.
4. He is also a member of the American Gastroenterological Association and North American Society for Pediatric Gastroenterology and Nutrition.
5. Amicus Therapeutics is a global biotechnology company focusing on therapies for rare and orphan diseases.
More articles on GI/endoscopy:
Global endoscopy devices market to reach $36.5B by 2022: 6 key trends
Umecrine Cognition names Dr. Bruce Scharschmidt senior development advisor: 4 points
UCLA researchers identify risk factors for tainted scopes’ bacteria transmission — 5 points
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
